Choosing the Right P2Y12 Inhibitor After PCI – JAMA Cardiology
JAMA Cardiology shared a post on LinkedIn about a recent article by Giuseppe Biondi-Zoccai et al., adding:
“Editorial: A network meta-analysis of randomized clinical trials comparing clopidogrel, prasugrel, and ticagrelor in patients with Acute Coronary Syndrome (ACS) undergoing percutaneous coronary intervention (PCI) indicates that prasugrel offers the most favorable efficacy-safety profile for reducing major adverse cardiovascular events, myocardial infarction, and stent thrombosis.
Clinicians are advised that selection of a P2Y12 inhibitor should be individualized to account for patient comorbidities, bleeding risk, and concurrent therapies, with clopidogrel and ticagrelor remaining appropriate alternatives for specific scenarios.”
Title: Prasugrel – The Default P2Y12 Inhibitor After PCI for ACS?
Authors: Giuseppe Biondi-Zoccai, Salvatore Giordano, Nicola Corcione
Stay updated with Hemostasis Today.
-
Oct 4, 2026, 15:06Vasiliki Gkalea: Journal of Clinical Medicine Launches Special Issue on Hematologic Thrombosis and Bleeding
-
Oct 4, 2026, 14:55Quentin Brebant: What Defines a High-Quality Red Blood Cell Concentrate?
-
Oct 4, 2026, 14:47Rana Al-Hrout: Recognizing Non-Anemic Iron Deficiency – Why Iron Matters Beyond Hemoglobin
-
Oct 4, 2026, 14:41David McIntosh: International Plasma Awareness Week 2026 – Closing the Global Plasma Gap
-
Oct 4, 2026, 14:33Pete Stibbs: CleanerVac Real-World Study Presented at VIVA and The VEINS 2026
-
Oct 4, 2026, 13:56Maria Elisa Mancuso: EHC 2026 Highlights the Unmet Needs of Women with Bleeding Disorders
-
Oct 4, 2026, 13:53Nirmal Shaji George: Individualizing Anticoagulation in Complex APS and Thrombocytopenia
-
Oct 4, 2026, 13:5210 Posts Not to Miss This Week
-
Oct 4, 2026, 13:45Suswapna Singh Rawat: The Clinical Significance of Coronary Plaque Stability